Moderna (MRNA) Prices 17.6M Share Common Offering at $76/Sh

Moderna (MRNA) May weekly IV at 151 into announces $1.25B common stock offering

Moderna (NASDAQ: MRNA) May weekly call option implied volatility is at 151, June is at 120; compared to its 52-week range of 51 to 172 announces $1.25B common stock offering. Call put ratio 1.5 calls to 1 put.

Dollar softer as euro rises on Franco-German proposal for recovery fund

By Saqib Iqbal Ahmed

NEW YORK (Reuters) - The U.S. dollar fell against the euro on Tuesday as the common currency added to Monday's gains on a Franco-German proposal for a fund that would offer grants to European Union regions and sectors hit hardest by the coronavirus pandemic.

Encouraging results from the trial of a vaccine for COVID-19 reduced demand for safe havens and the greenback rose to a near one-month high against the Japanese yen. .

Germany and France, whose agreements usually pave the way for broader EU deals, proposed that the European Commission borrow... More

After-Hours Stock Movers 05/18: (ABUS) (DAC) (BIDU) Higher; (BLPH) (GMDA) (GOSS) Lower (more...)

After-Hours Stock Movers:

Arbutus Biopharma Corporation (Nasdaq: ABUS) 55% HIGHER; reports positive follow-up data from a Phase 1a/1b clinical trial (AB-729-001) in chronic HBV subjects on nucleos(t)ide therapy who received a single subcutaneous injection of 60 mg of AB-729, a proprietary GalNAc delivered RNAi compound.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) 14.7% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering.

Gamida Cell... More

Trump says he is taking hydroxychloroquine despite FDA warning

By Jeff Mason and Steve Holland

WASHINGTON (Reuters) - U.S. President Donald Trump, in a surprise announcement, said on Monday he is taking hydroxychloroquine as a preventive medicine against the coronavirus despite medical warnings about the use of the malaria drug.

Trump volunteered the disclosure during a question-and-answer session with reporters at the White House as he met restaurant executives whose businesses are reeling from the impact of the virus.

"I'm taking hydroxychloroquine," Trump said. "I've been taking it for the last week and a half. A pill every day."

Weeks ago,... More

Moderna (MRNA) is Said to Offer Shares at $75 to $77.50 Each - Bloomberg

Moderna (NASDAQ: MRNA) is Said to Offer Shares at $75 to $77.50 Each - Bloomberg

Moderna (MRNA) Announces Proposed $1.25 Billion Public Offering of Shares of Common Stock

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has commenced an underwritten public offering of $1.25 billion in shares of common stock. In addition, Moderna expects to grant the underwriters a 30-day option to purchase up... More

Moderna (MRNA) PT Raised to 'Street High' $108 at Oppenheimer

Oppenheimer analyst Hartaj Singh raised the price target on Moderna (NASDAQ: MRNA) to $108.00 (from $62.00) while maintaining an Outperform rating.

The analyst commented, "Moderna (MRNA) today announced positive interim Phase 1 data from mRNA-1273 against novel SARS-CoV-2. All participants across three doses (25, 100, 250 µg) seroconverted by... More

Moderna (MRNA) call put ratio 2.4 calls to 1 put after Phase 1 coronavirus vaccine data

Moderna (NASDAQ: MRNA) May weekly call option implied volatility is at 216, June is at 133; compared to its 52-week range of 50 to 172 after Moderna said its experimental COVID-19 vaccine showed promise in a small early-stage trial, with the vaccine producing virus-neutralizing antibodies similar to that found in recovered patients.

Coronavirus vaccine from Moderna appears safe, shows promise in data from eight people

By Julie Steenhuysen and Saumya Joseph

(Reuters) - Moderna Inc's (NASDAQ: MRNA) experimental COVID-19 vaccine, the first to be tested in the United States, produced protective antibodies in a small group of healthy volunteers, according to very early data released by the biotech company on Monday.

The data comes from eight people who took part in a 45-subject safety trial that kicked off in March. The Moderna vaccine is one of more than 100 under development intended to protect against the novel coronavirus that has infected more than 4.7 million people globally and killed over... More

UPDATE: Moderna (MRNA) PT Raised to 'Street High' $105 at Goldman Sachs

(Updated - May 18, 2020 10:00 AM EDT)

Goldman Sachs analyst Salveen Richter reiterated a Buy rating and raised his price target on Moderna (NASDAQ: MRNA) to $105.00 (from $63.00) following positive COVID vaccine data.

The price target is a new 'Street High'.

For an... More

Pre-Open Movers 05/18: (SRNE) (MRNA) (FLGT) Higher; (CTRC) (FSCT) (GSX) Lower (more...)

Today's Pre-Open Stock Movers

Centric Brands Inc. (NASDAQ: CTRC) 52.8% LOWER; announced today that it has entered into a Restructuring Support Agreement (RSA or the agreement) with substantially all of the Companys secured lenders, led by certain funds managed by Blackstone (Blackstone), Ares Management Corporation (Ares), and HPS Investment Partners (HPS), to recapitalize the Company, provide $435 million in debtor-in-possession financing and allow the Company to operate without interruption throughout the restructuring process.

Sorrento Therapeutics (NASDAQ: SRNE) 35.5% HIGHER; Adds to Friday's Gain, Up 35%... More

Moderna (MRNA) IV at 110 into shares rallying before the bell on Phase 1 coronavirus vaccine data

Moderna (NASDAQ: MRNA) May weekly call option implied volatility is at 110, July is at 105; compared to its 52-week range of 50 to 172 into Phase 1 coronavirus vaccine data.

Moderna (MRNA) Surges 20%+ on Positive Interim Phase 1 Data for its mRNA Coronavirus Vaccine

Moderna (NASDAQ: MRNA) shares surge 23% following positive Phase 1 Data for its mRNA Coronavirus Vaccine.

Moderna (MRNA) Announces Positive Interim Phase 1 Data for its mRNA Coronavirus Vaccine

Moderna, Inc., (Nasdaq: MRNA) announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Immunogenicity data are currently available for the 25 µg and 100 µg dose level (ages 18-55) after two doses (day 43) and at the 250 µg level (ages 18-55) after one dose (day 29). Dose dependent increases in immunogenicity were seen across the three dose levels, and between prime and boost within the 25 µg and 100 µg... More

S&P 500 closes at 10-week high on vaccine hopes, stimulus pledge

By Chuck Mikolajczak

NEW YORK (Reuters) - U.S. stocks jumped on Monday, and the S&P 500 closed at a 10-week high, on encouraging early-stage data for a potential coronavirus vaccine and on the promise of more stimulus to lift an economy beaten down by the pandemic.

Drugmaker Moderna Inc (NASDAQ: MRNA) surged 19.96% after the company said its experimental COVID-19 vaccine showed promising results in a small early-stage trial.

After rallying more than 32% from a multi-year low hit in March, the S&P 500 had been trading in a... More

European shares surge as recovery hopes boost cyclicals

By Sruthi Shankar

(Reuters) - European shares enjoyed their best day in nearly eight weeks on Monday, with cyclical sectors soaring as an easing of lockdowns and an encouraging report on a potential COVID-19 vaccine boosted hopes of a swifter economic recovery.

Miners leapt 8%, leading Europe's sectoral gains, while automakers , oil and gas and travel and leisure indexes - typically reliant on the health of a global economy that has taken a battering due to the coronavirus crisis - gained between 6.5% and 7.9%.

Germany's auto-heavy DAX surged 5.7% to its highest level in over two... More

Oil jumps to two-month high on easing lockdowns, positive vaccine results

By Scott DiSavino

NEW YORK (Reuters) - Oil prices on Monday jumped to their highest in over two months on positive early results on a potential coronavirus vaccine, optimism about a resumption in economic activity and signs producers were following through on planned output reductions.

Brent futures for July delivery rose $2.31, or 7.1%, to $34.81 a barrel, while U.S. West Texas Intermediate (WTI) crude rose $2.39, or 8.1%, to $31.82.

That was the highest settles for Brent and WTI since March 11, just a few days after prices started to collapse following the failure of a production cut... More

Global shares, oil rally on vaccine hopes, lockdown easing

By Herbert Lash

NEW YORK (Reuters) - A gauge of global equity markets surged almost 3% on Monday and oil rallied to highs last seen in mid-April as data from an early-stage trial for a coronavirus vaccine lifted hopes of a faster recovery from the pandemic-driven economic slump.

Warm weather enticed people in countries across the world to emerge from coronavirus lockdowns as centers of the outbreak from New York to Italy and Spain gradually lift restrictions that have kept millions cooped up for months.

Investors have cheered any positive development by drugmakers' vaccine trials... More

Moderna (MRNA) Says Dr. Slaoui Resigned From Board to Join White House’s Operation Warp Speed Initiative

Moderna, Inc., (Nasdaq: MRNA) announced that Dr. Moncef Slaoui has resigned from Modernas Board of Directors upon appointment of his new role to oversee the White Houses Operation Warp Speed initiative. Dr. Slaoui joined Modernas Board of Directors in 2017.

I would like to thank Moncef for his critical insights and... More

Trump said down to 14 vaccine candidates, from over 100

Trump said down to 14 vaccine candidates, from over 100

Moderna (MRNA) Gives Up Gains as Trump Talks Vaccines

Moderna (NASDAQ: MRNA) gives up gains as Trump doesn't discuss specific vaccines, just saying we could have one by year-end.

Keenly-watched COVID-19 vaccine 'won't be expensive', developer says

By Kate Kelland

LONDON (Reuters) - A keenly-watched COVID-19 vaccine will be priced to allow as wide as possible access to it, if it proves successful, and will be made at huge scale to keep costs down and supply up, said the Oxford University professor co-leading its development.

Adrian Hill, director of Oxford's Jenner Institute, which has teamed up with the drugmaker AstraZeneca (NYSE: AZN) to develop the vaccine, said ensuring wide distribution and low cost have been central to the project from the start.

"This not going to be an... More

U.S. Health Secretary Azar says hopes to have one or more safe and effective COVID vaccines by year-end - FBN

U.S. Health Secretary Azar says hopes to have one or more safe and effective COVID vaccines by year-end - FBN

Moderna (MRNA) on Watch Into Trump Update on COVID Vaccine

Moderna (NASDAQ: MRNA) shares are on watch after Conway said President Trump will announce a COVID vaccine update in the Rose Garden.

In the U.S., Moderna's vaccine candidate is the furthest along although many other companies have vaccines in... More